OTCMKTS:VCKAU Vickers Vantage Corp. I (VCKAU) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free VCKAU Stock Alerts $9.60 -0.71 (-6.89%) (As of 11/10/2022) Add Compare Share Share Today's Range$8.61▼$10.1550-Day Range$9.60▼$9.6052-Week Range$8.61▼$10.94Volume2,800 shsAverage Volume5,774 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vickers Vantage Corp. I alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Vickers Vantage Corp. I Stock (OTCMKTS:VCKAU)As of November 10, 2022, Vickers Vantage Corp. I was acquired by Scilex Holding Company, in a reverse merger transaction. Vickers Vantage Corp. I does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Singapore.Read More VCKAU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCKAU Stock News HeadlinesApril 30, 2024 | americanbankingnews.comVickers Vantage Corp. I (OTCMKTS:VCKAU) Stock Price Down 6.9%January 22, 2024 | wsj.comOracle Corp.May 8, 2024 | Smallcaps Daily (Ad)The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.December 6, 2023 | wsj.comNewsStarbucks Corp.SBUXAugust 4, 2023 | wsj.comRTX Corp.May 18, 2023 | uk.investing.comScilex Holding Co (SCLX)May 14, 2023 | finance.yahoo.comSorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual AccountsMay 4, 2023 | finance.yahoo.comScilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back PainMay 8, 2024 | Smallcaps Daily (Ad)The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.April 17, 2023 | finance.yahoo.comScilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa RegionMarch 21, 2023 | finance.yahoo.comScilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management ProductsMarch 1, 2023 | forbes.comBoras CorporationFebruary 18, 2023 | finance.yahoo.comChip Resistor Market Size & Share to Surpass $2.0 Billion by 2028 | Vantage Market ResearchFebruary 17, 2023 | finance.yahoo.comSorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)February 4, 2023 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of StockholdersFebruary 2, 2023 | finance.yahoo.comScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common StockJanuary 5, 2023 | finance.yahoo.comVantage Data Centers Names Purnima Wagle as Chief Information OfficerNovember 10, 2022 | marketwatch.comVickers Vantage Shares Down 10% After Closing Scilex DealOctober 31, 2022 | finance.yahoo.comScilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business CombinationOctober 2, 2022 | uk.finance.yahoo.comVickers Vantage Corp. I (VCKA)August 31, 2022 | investorplace.comSorrento Therapeutics (SRNE) Pops on FDA Fast Track DesignationAugust 24, 2022 | finance.yahoo.comVickers Vantage Corp. I (VCKAU)August 17, 2022 | finance.yahoo.comScilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North AfricaJune 14, 2022 | finance.yahoo.comScilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.May 18, 2022 | finance.yahoo.comScilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back PainMay 16, 2022 | finance.yahoo.comScilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination between Scilex and VickersApril 27, 2022 | finance.yahoo.comScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.See More Headlines Receive VCKAU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vickers Vantage Corp. I and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Shell Companies Sub-IndustryN/A Current SymbolOTCMKTS:VCKAU CUSIPN/A CIK1820190 Webwww.vickersvantage.com Phone646 974 8301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Chien-Chuen Chi C.F.A. (Age 54)Exec. Chairman & CEO Mr. Chris Ho (Age 33)CFO & Director Key Competitors10X Capital Venture AcquisitionOTCMKTS:VCVCU890 5th Avenue PartnersOTCMKTS:ENFAUACE Convergence AcquisitionOTCMKTS:ACEVUACON S2 AcquisitionOTCMKTS:STWOUAlpha Capital AcquisitionOTCMKTS:ASPCUView All Competitors VCKAU Stock Analysis - Frequently Asked Questions How have VCKAU shares performed in 2024? Vickers Vantage Corp. I's stock was trading at $9.60 at the beginning of 2024. Since then, VCKAU stock has increased by 0.0% and is now trading at $9.60. View the best growth stocks for 2024 here. How do I buy shares of Vickers Vantage Corp. I? Shares of VCKAU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VCKAU) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vickers Vantage Corp. I Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
